Fig. 1: BNT162b2-induced IgG concentrations and virus neutralization titres.
From: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Participants were immunized with BNT162b2 on days 1 and 22 (n = 12 per dose cohort; from day 22 onwards, n = 11 for the 1-μg and 10-μg dose cohorts). Arrowheads indicate days of vaccination. Pre-dose responses (pre) across all dose levels were combined. Samples from individuals who had recovered from infection with SARS-CoV-2 or COVID-19 (‘human convalescent samples’ (HCS)) (n = 38) were obtained at least 14 days after PCR-confirmed diagnosis and at a time at which the donors were no longer symptomatic. Each serum was tested in duplicate and geometric mean 50% (pseudo)neutralizing titres (GMTs) were plotted. a, SARS-CoV-2 50% neutralization titres (VNT50). For values below the lower limit of quantification (LLOQ; 20), LLOQ/2 values are plotted. Group GMTs (values above bars) with 95% confidence intervals. b, Pseudovirus 50% neutralization titres (pVNT50) across a panel of pseudoviruses displaying SARS-CoV-2 S variants, including Wuhan-Hu-1 (wild type), B.1.1.298 with four point mutations (B.1.1.298 (Δ4)) and B.1.351 with all ten lineage-defining mutations (B.1.351 (Δ10)) or eight of those mutations (B.1.351 (Δ8)); 30-μg dose cohort, n = 1 for day 29, n = 11 for day 43.
